The next-generation antibody is designed to be more specific and often more potent than traditional monoclonal antibodies. Next-generation antibody strategies are required to engineer a useful therapeutic combining antibody, payload, linker, and conjugation method while ensuring stability, targeted delivery, and limited off-target effects.
The market for next generation antibody market is forecasted to grow during the forecast years due to the huge success of the discovery and development of monoclonal antibodies, rising prevalence of chronic disorders and advent of technology supporting R&D activities are anticipated to drive market. In addition, the innovative R&D approaches incorporated by market players to develop effective and advanced drugs is expected to offer significant growth opportunities in the market during the forecast period.
The "Global Next Generation Antibody Market Analysis to 2027" is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of next generation antibody market with detailed market segmentation by therapeutic area, technology, and geography. The global next generation antibody market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading next generation antibody market players and offers key trends and opportunities in the market.
The global next generation antibody market is segmented on the basis of therapeutic area and technology. Based on the therapeutic area the market is segmented as oncology and autoimmune or inflammatory. On the basis of technology the next generation antibody is classified as antibody-drug conjugates, bispecific antibodies, FC engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global next generation antibody market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The next generation antibody market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting next generation antibody market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the next generation antibody market in these regions.
The reports cover key developments in the next generation antibody market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from next generation antibody market are anticipated to lucrative growth opportunities in the future with the rising demand for next generation antibody market in the global market. Below mentioned is the list of few companies engaged in the next generation antibody market.
The report also includes the profiles of key next generation antibody market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- F. Hoffmann-La Roche Ltd
- Kyowa Hakko Kirin Co., Ltd.
- Seattle Genetics, Inc.
- ImmunoGen, Inc.
- Bristol-Myers Squibb Company
- Pfizer, Inc.
- Amgen, Inc.
- Bayer AG
- Xencor, Inc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.